According to the research report, the global market for Transarterial Chemoembolization (TACE) should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

China Transarterial Chemoembolization (TACE) market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

The United States Transarterial Chemoembolization (TACE) market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.

In terms of type, Chemotherapeutic Agents segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospitals has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.

The global key manufacturers of Transarterial Chemoembolization (TACE) include Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG and Pfizer Inc., etc. In 2022, the global top five players hold a share approximately % in terms of revenue.

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.

This report aims to provide a comprehensive study of the global market for Transarterial Chemoembolization (TACE). Report Highlights:

(1) Global Transarterial Chemoembolization (TACE) market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.

(2) Global Transarterial Chemoembolization (TACE) market competitive situation, revenue and market share, from 2018 to 2022.

(3) China Transarterial Chemoembolization (TACE) market competitive situation, revenue and market share, from 2018 to 2022.

(4) Global Transarterial Chemoembolization (TACE) segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Transarterial Chemoembolization (TACE) segment by type and by application and regional segment by type and by application.

(6) Transarterial Chemoembolization (TACE) industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Chemotherapeutic Agents

Radio Therapeutic Agents

Drug-eluting Particles

Others

Market segment by application, can be divided into

Hospitals

Clinics

Cancer Research Centers

Market segment by players, this report covers

Questex

Siemens Healthcare GmbH

Bellicum Pharmaceuticals Inc.

Boston Scientific

Cook Group

Hikma Pharmaceuticals

Nippon Kayaku

Novartis AG

Pfizer Inc.

Spectrum Pharmaceutical

Roche Holding AG

Celgene

Bayer AG

Merck & Co., Inc.

SingHealth

1 Market Overview

1.1 Product Overview and Scope of Transarterial Chemoembolization (TACE)

1.2 Global Transarterial Chemoembolization (TACE) Market Size and Forecast

1.3 China Transarterial Chemoembolization (TACE) Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Transarterial Chemoembolization (TACE) Share in Global Market, 2018-2029

1.4.2 Transarterial Chemoembolization (TACE) Market Size: China VS Global, 2018-2029

1.5 Transarterial Chemoembolization (TACE) Market Dynamics

1.5.1 Transarterial Chemoembolization (TACE) Market Drivers

1.5.2 Transarterial Chemoembolization (TACE) Market Restraints

1.5.3 Transarterial Chemoembolization (TACE) Industry Trends

1.5.4 Transarterial Chemoembolization (TACE) Industry Policy

2 Global Competitive Situation by Company

2.1 Global Transarterial Chemoembolization (TACE) Revenue by Company (2018-2023)

2.2 Global Transarterial Chemoembolization (TACE) Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Transarterial Chemoembolization (TACE) Concentration Ratio

2.4 Global Transarterial Chemoembolization (TACE) Mergers & Acquisitions, Expansion Plans

2.5 Global Transarterial Chemoembolization (TACE) Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Transarterial Chemoembolization (TACE) Revenue by Company (2018-2023)

3.2 China Transarterial Chemoembolization (TACE) Transarterial Chemoembolization (TACE) Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Transarterial Chemoembolization (TACE), Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)

4 Industry Chain Analysis

4.1 Transarterial Chemoembolization (TACE) Industry Chain

4.2 Transarterial Chemoembolization (TACE) Upstream Analysis

4.3 Transarterial Chemoembolization (TACE) Midstream Analysis

4.4 Transarterial Chemoembolization (TACE) Downstream Analysis

5 Sights by Type

5.1 Transarterial Chemoembolization (TACE) Classification

5.1.1 Chemotherapeutic Agents

5.1.2 Radio Therapeutic Agents

5.1.3 Drug-eluting Particles

5.1.4 Others

5.2 By Type, Global Transarterial Chemoembolization (TACE) Market Size & CAGR, 2018 VS 2022 VS 2029

5.3 By Type, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029

6 Sights by Application

6.1 Transarterial Chemoembolization (TACE) Segment by Application

6.1.1 Hospitals

6.1.2 Clinics

6.1.3 Cancer Research Centers

6.2 By Application, Global Transarterial Chemoembolization (TACE) Market Size & CAGR, 2018 VS 2022 VS 2029

6.3 By Application, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029

7 Sales Sights by Region

7.1 By Region, Global Transarterial Chemoembolization (TACE) Market Size, 2018 VS 2022 VS 2029

7.2 By Region, Global Transarterial Chemoembolization (TACE) Market Size, 2018-2029

7.3 North America

7.3.1 North America Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029

7.3.2 By Country, North America Transarterial Chemoembolization (TACE) Market Size Market Share

7.4 Europe

7.4.1 Europe Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029

7.4.2 By Country, Europe Transarterial Chemoembolization (TACE) Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029

7.5.2 By Country/Region, Asia Pacific Transarterial Chemoembolization (TACE) Market Size Market Share

7.6 South America

7.6.1 South America Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029

7.6.2 By Country, South America Transarterial Chemoembolization (TACE) Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Transarterial Chemoembolization (TACE) Market Size & CAGR，2018 VS 2022 VS 2029

8.2 By Country, Global Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.3 U.S.

8.3.1 U.S. Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.3.2 By Company, U.S. Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.3.3 By Type, U.S. Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.3.4 By Application, U.S. Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.4.2 By Company, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.4.3 By Type, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.4.4 By Application, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.5 China

8.5.1 China Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.5.2 By Company, China Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.5.3 By Type, China Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.5.4 By Application, China Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.6.2 By Company, Japan Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.6.3 By Type, Japan Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.6.4 By Application, Japan Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.7.2 By Company, South Korea Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.7.3 By Type, South Korea Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.7.4 By Application, South Korea Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.8.2 By Company, Southeast Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.8.3 By Type, Southeast Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.8.4 By Application, Southeast Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.9 India

8.9.1 India Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.9.2 By Company, India Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.9.3 By Type, India Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.9.4 By Application, India Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.10 Middle East & Asia

8.10.1 Middle East & Asia Transarterial Chemoembolization (TACE) Market Size, 2018-2029

8.10.2 By Company, Middle East & Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

8.10.3 By Type, Middle East & Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

8.10.4 By Application, Middle East & Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

9 Global Manufacturers Profile

9.1 Questex

9.1.1 Questex Company Information, Head Office, Market Area and Industry Position

9.1.2 Questex Company Profile and Main Business

9.1.3 Questex Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.1.4 Questex Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.1.5 Questex Recent Developments

9.2 Siemens Healthcare GmbH

9.2.1 Siemens Healthcare GmbH Company Information, Head Office, Market Area and Industry Position

9.2.2 Siemens Healthcare GmbH Company Profile and Main Business

9.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.2.5 Siemens Healthcare GmbH Recent Developments

9.3 Bellicum Pharmaceuticals Inc.

9.3.1 Bellicum Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position

9.3.2 Bellicum Pharmaceuticals Inc. Company Profile and Main Business

9.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.3.5 Bellicum Pharmaceuticals Inc. Recent Developments

9.4 Boston Scientific

9.4.1 Boston Scientific Company Information, Head Office, Market Area and Industry Position

9.4.2 Boston Scientific Company Profile and Main Business

9.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.4.5 Boston Scientific Recent Developments

9.5 Cook Group

9.5.1 Cook Group Company Information, Head Office, Market Area and Industry Position

9.5.2 Cook Group Company Profile and Main Business

9.5.3 Cook Group Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.5.5 Cook Group Recent Developments

9.6 Hikma Pharmaceuticals

9.6.1 Hikma Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

9.6.2 Hikma Pharmaceuticals Company Profile and Main Business

9.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.6.5 Hikma Pharmaceuticals Recent Developments

9.7 Nippon Kayaku

9.7.1 Nippon Kayaku Company Information, Head Office, Market Area and Industry Position

9.7.2 Nippon Kayaku Company Profile and Main Business

9.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.7.5 Nippon Kayaku Recent Developments

9.8 Novartis AG

9.8.1 Novartis AG Company Information, Head Office, Market Area and Industry Position

9.8.2 Novartis AG Company Profile and Main Business

9.8.3 Novartis AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.8.5 Novartis AG Recent Developments

9.9 Pfizer Inc.

9.9.1 Pfizer Inc. Company Information, Head Office, Market Area and Industry Position

9.9.2 Pfizer Inc. Company Profile and Main Business

9.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.9.5 Pfizer Inc. Recent Developments

9.10 Spectrum Pharmaceutical

9.10.1 Spectrum Pharmaceutical Company Information, Head Office, Market Area and Industry Position

9.10.2 Spectrum Pharmaceutical Company Profile and Main Business

9.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.10.5 Spectrum Pharmaceutical Recent Developments

9.11 Roche Holding AG

9.11.1 Roche Holding AG Company Information, Head Office, Market Area and Industry Position

9.11.2 Roche Holding AG Company Profile and Main Business

9.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.11.5 Roche Holding AG Recent Developments

9.12 Celgene

9.12.1 Celgene Company Information, Head Office, Market Area and Industry Position

9.12.2 Celgene Company Profile and Main Business

9.12.3 Celgene Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.12.5 Celgene Recent Developments

9.13 Bayer AG

9.13.1 Bayer AG Company Information, Head Office, Market Area and Industry Position

9.13.2 Bayer AG Company Profile and Main Business

9.13.3 Bayer AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.13.5 Bayer AG Recent Developments

9.14 Merck & Co., Inc.

9.14.1 Merck & Co., Inc. Company Information, Head Office, Market Area and Industry Position

9.14.2 Merck & Co., Inc. Company Profile and Main Business

9.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.14.5 Merck & Co., Inc. Recent Developments

9.15 SingHealth

9.15.1 SingHealth Company Information, Head Office, Market Area and Industry Position

9.15.2 SingHealth Company Profile and Main Business

9.15.3 SingHealth Transarterial Chemoembolization (TACE) Models, Specifications and Application

9.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

9.15.5 SingHealth Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. Transarterial Chemoembolization (TACE) Market Size & CAGR: China VS Global, (US$ Million), 2018-2029

Table 2. Transarterial Chemoembolization (TACE) Market Restraints

Table 3. Transarterial Chemoembolization (TACE) Market Trends

Table 4. Transarterial Chemoembolization (TACE) Industry Policy

Table 5. Global Transarterial Chemoembolization (TACE) Revenue by Company (2018-2023) & (US$ million)

Table 6. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Company (2018-2023)

Table 7. Global Transarterial Chemoembolization (TACE) Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Transarterial Chemoembolization (TACE) Mergers & Acquisitions, Expansion Plans

Table 9. Global Transarterial Chemoembolization (TACE) Manufacturers Product Type

Table 10. China Transarterial Chemoembolization (TACE) Revenue by Company (2018-2023) & (US$ million)

Table 11. China Transarterial Chemoembolization (TACE) Revenue Market Share by Company (2018-2023)

Table 12. Global Key Players of Transarterial Chemoembolization (TACE) Upstream (Raw Materials)

Table 13. Global Transarterial Chemoembolization (TACE) Typical Customers

Table 14. Transarterial Chemoembolization (TACE) Typical Distributors

Table 15. By Type, Global Transarterial Chemoembolization (TACE) Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 16. By Application, Global Transarterial Chemoembolization (TACE) Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million

Table 17. By Region, Global Transarterial Chemoembolization (TACE) Market Size, 2018 VS 2022 VS 2029, US$ Million

Table 18. By Region, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029, US$ Million

Table 19. By Country, Global Transarterial Chemoembolization (TACE) Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million

Table 20. By Country, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029, US$ Million

Table 21. By Country, Global Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2029

Table 22. Questex Company Information, Head Office, Market Area and Industry Position

Table 23. Questex Company Profile and Main Business

Table 24. Questex Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 25. Questex Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 26. Questex Recent Developments

Table 27. Siemens Healthcare GmbH Company Information, Head Office, Market Area and Industry Position

Table 28. Siemens Healthcare GmbH Company Profile and Main Business

Table 29. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 30. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 31. Siemens Healthcare GmbH Recent Developments

Table 32. Bellicum Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position

Table 33. Bellicum Pharmaceuticals Inc. Company Profile and Main Business

Table 34. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 35. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 36. Bellicum Pharmaceuticals Inc. Recent Developments

Table 37. Boston Scientific Company Information, Head Office, Market Area and Industry Position

Table 38. Boston Scientific Company Profile and Main Business

Table 39. Boston Scientific Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 40. Boston Scientific Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 41. Boston Scientific Recent Developments

Table 42. Cook Group Company Information, Head Office, Market Area and Industry Position

Table 43. Cook Group Company Profile and Main Business

Table 44. Cook Group Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 45. Cook Group Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 46. Cook Group Recent Developments

Table 47. Hikma Pharmaceuticals Company Information, Head Office, Market Area and Industry Position

Table 48. Hikma Pharmaceuticals Company Profile and Main Business

Table 49. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 50. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 51. Hikma Pharmaceuticals Recent Developments

Table 52. Nippon Kayaku Company Information, Head Office, Market Area and Industry Position

Table 53. Nippon Kayaku Company Profile and Main Business

Table 54. Nippon Kayaku Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 55. Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 56. Nippon Kayaku Recent Developments

Table 57. Novartis AG Company Information, Head Office, Market Area and Industry Position

Table 58. Novartis AG Company Profile and Main Business

Table 59. Novartis AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 60. Novartis AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 61. Novartis AG Recent Developments

Table 62. Pfizer Inc. Company Information, Head Office, Market Area and Industry Position

Table 63. Pfizer Inc. Company Profile and Main Business

Table 64. Pfizer Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 65. Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 66. Pfizer Inc. Recent Developments

Table 67. Spectrum Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 68. Spectrum Pharmaceutical Company Profile and Main Business

Table 69. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 70. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 71. Spectrum Pharmaceutical Recent Developments

Table 72. Roche Holding AG Company Information, Head Office, Market Area and Industry Position

Table 73. Roche Holding AG Company Profile and Main Business

Table 74. Roche Holding AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 75. Roche Holding AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 76. Roche Holding AG Recent Developments

Table 77. Celgene Company Information, Head Office, Market Area and Industry Position

Table 78. Celgene Company Profile and Main Business

Table 79. Celgene Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 80. Celgene Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 81. Celgene Recent Developments

Table 82. Bayer AG Company Information, Head Office, Market Area and Industry Position

Table 83. Bayer AG Company Profile and Main Business

Table 84. Bayer AG Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 85. Bayer AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 86. Bayer AG Recent Developments

Table 87. Merck & Co., Inc. Company Information, Head Office, Market Area and Industry Position

Table 88. Merck & Co., Inc. Company Profile and Main Business

Table 89. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 90. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 91. Merck & Co., Inc. Recent Developments

Table 92. SingHealth Company Information, Head Office, Market Area and Industry Position

Table 93. SingHealth Company Profile and Main Business

Table 94. SingHealth Transarterial Chemoembolization (TACE) Models, Specifications and Application

Table 95. SingHealth Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023

Table 96. SingHealth Recent Developments

List of Figure

Figure 1. Transarterial Chemoembolization (TACE) Picture

Figure 2. Global Transarterial Chemoembolization (TACE) Industry Market Size and Forecast (US$ million) & (2018-2029)

Figure 3. China Transarterial Chemoembolization (TACE) Revenue and Forecast (US$ million) & (2018-2029)

Figure 4. 2018-2029 China Transarterial Chemoembolization (TACE) Market Share of Global

Figure 5. Global Transarterial Chemoembolization (TACE) Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 6. Global Transarterial Chemoembolization (TACE) Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023

Figure 7. China Transarterial Chemoembolization (TACE) Key Participants, Market Share, 2021 VS 2022 VS 2023

Figure 8. China Transarterial Chemoembolization (TACE) Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023

Figure 9. Transarterial Chemoembolization (TACE) Industry Chain

Figure 10. Chemotherapeutic Agents

Figure 11. Radio Therapeutic Agents

Figure 12. Drug-eluting Particles

Figure 13. Others

Figure 14. By Type, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029, US$ Million

Figure 15. By Type, Global Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2029

Figure 16. Hospitals

Figure 17. Clinics

Figure 18. Cancer Research Centers

Figure 19. By Application, Global Transarterial Chemoembolization (TACE) Revenue, 2018-2029, US$ Million

Figure 20. By Application, Global Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2029

Figure 21. By Region, Global Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2029

Figure 22. North America Transarterial Chemoembolization (TACE) Revenue & Forecasts, 2018-2029, US$ Million

Figure 23. By Country, North America Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

Figure 24. Europe Transarterial Chemoembolization (TACE) Revenue & Forecasts, 2018-2029, US$ Million

Figure 25. By Country, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

Figure 26. Asia Pacific Transarterial Chemoembolization (TACE) Revenue & Forecasts, 2018-2029, US$ Million

Figure 27. By Country/Region, Asia Pacific Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

Figure 28. South America Transarterial Chemoembolization (TACE) Revenue & Forecasts, 2018-2029, US$ Million

Figure 29. By Country, South America Transarterial Chemoembolization (TACE) Revenue Market Share, 2018-2023

Figure 30. Middle East & Africa Transarterial Chemoembolization (TACE) Revenue & Forecasts, 2018-2029, US$ Million

Figure 31. U.S. Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 32. By Company, U.S. Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 33. By Type, U.S. Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 34. By Application, U.S. Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 35. Europe Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 36. By Company, Europe Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 37. By Type, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 38. By Application, Europe Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 39. China Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 40. By Company, China Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 41. By Type, China Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 42. By Application, China Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 43. Japan Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 44. By Company, Japan Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 45. By Type, Japan Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 46. By Application, Japan Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 47. South Korea Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 48. By Company, South Korea Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 49. By Type, South Korea Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 50. By Application, South Korea Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 51. Southeast Asia Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 52. By Company, Southeast Asia Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 53. By Type, Southeast Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 54. By Application, Southeast Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 55. India Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 56. By Company, India Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 57. By Type, India Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 58. By Application, India Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 59. Middle East & Asia Transarterial Chemoembolization (TACE) Revenue, 2018-2029, (US$ Million)

Figure 60. By Company, Middle East & Asia Transarterial Chemoembolization (TACE) Market Share, 2018-2023

Figure 61. By Type, Middle East & Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 62. By Application, Middle East & Asia Transarterial Chemoembolization (TACE) Revenue Market Share, 2022 VS 2029

Figure 63. Research Methodology

Figure 64. Breakdown of Primary Interviews

Figure 65. Bottom-up Approaches

Figure 66. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)